Portal Hypertension Management Market Report 2026

Portal Hypertension Management Market Overview

• Portal Hypertension Management market size has reached to $3.27 billion in 2025 • Expected to grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 5.9% • Growth Driver: Increasing Prevalence Of Liver Diseases Such As Hepatitis Fuels Portal Hypertension Market • Market Trend: Adoption Minimally Invasive Devices For Portal Hypertension Management • North America was the largest region in 2025.

What Is Covered Under Portal Hypertension Management Market?

Portal hypertension management refers to the treatment and prevention of complications arising from increased pressure in the portal vein system, often due to liver cirrhosis. It involves measures to reduce portal pressure, such as lifestyle changes, medications (like beta-blockers), and procedures such as variceal banding placement to prevent or manage complications such as variceal bleeding and ascites. The main treatment for portal hypertension management is medication, non-surgical procedure, and surgery. Portal hypertension medication typically refers to drugs such as nonselective beta-blockers, vasoconstrictors, diuretics, and antibiotics used to manage complications such as variceal bleeding, ascites, and bacterial infections in patients with elevated portal pressure. The procedure involves transjugular intrahepatic portosystemic shunt (TIPS) and is utilized by various end users including hospitals, specialty clinics, and others.

What Is The Portal Hypertension Management Market Growth Forecast?

The portal hypertension management market size is expected to see strong growth in the next few years. It will grow to $4.39 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing demand for advanced liver disease management, rising adoption of t i p s procedures, growing focus on complication prevention, expansion of specialty liver clinics, increasing investment in precision hepatology treatments. Major trends in the forecast period include increasing adoption of minimally invasive treatment approaches, growing use of endoscopic variceal management techniques, rising focus on early intervention strategies, expansion of combination drug therapies, enhanced monitoring of portal pressure levels.

Global Portal Hypertension Management Market Segmentation

1) By Treatment Type: Medications, Non-Surgical Procedures, Surgery 2) By Procedure Type: Transjugular Intrahepatic Portosystemic Shunt (TIPS), Other Procedure Types 3) By End-User: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Medications: Beta-Blockers, Vasodilators, Diuretics, Antibiotics, Other Medications 2) By Non-Surgical Procedures: Endoscopic Variceal Ligation (EVL), Endoscopic Sclerotherapy, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Balloon Occlusion 3) By Surgery: Liver Transplantation, Portosystemic Shunt Surgery, Surgical Decompression Of Portal Vein, Other Surgical Procedures

What Is The Driver Of The Portal Hypertension Management Market?

An increasing prevalence of liver diseases is expected to propel the growth of the portal hypertension management market going forward. Liver disease refers to a range of conditions that affect the liver's structure or function, often leading to symptoms such as jaundice, fatigue, and abdominal pain, with causes including viral infections, alcohol abuse, or metabolic disorders. Liver diseases are occurring due to alcohol consumption, viral hepatitis infections, obesity-related fatty liver disease, and metabolic disorders. Portal hypertension management in liver disease aims to reduce pressure in the portal vein system, which helps alleviate complications such as variceal bleeding, ascites, and hepatic encephalopathy, improving patient outcomes. For instance, in July 2023, according to the World Health Organization (WHO), a Switzerland-based health agency, the Western Pacific Region faces a growing burden of liver diseases, with 116 million people living with hepatitis B and 10 million with hepatitis C in 2023. Despite 3 million new infections annually, diagnosis and treatment rates remain low, fueling the increasing prevalence of liver cirrhosis and liver cancer. Therefore, the increasing prevalence of liver diseases is driving the portal hypertension management industry.

Key Players In The Global Portal Hypertension Management Market

Major companies operating in the portal hypertension management market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Gilead Sciences Inc., Merck & Co., Boehringer Ingelheim International GmbH, Amneal Pharmaceuticals LLC, Lupin Ltd., Daiichi Sankyo, Dr. Falk Pharma GmbH, Cumberland Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Ipsen Pharma, Eisai Co. Ltd., Johnson & Johnson

Global Portal Hypertension Management Market Trends and Insights

Major companies in the portal hypertension management market are adopting advanced minimally invasive devices to enhance treatment outcomes and reduce procedural risks. Minimally invasive devices are medical instruments or tools designed to perform procedures with minimal disruption to surrounding tissues, typically through small incisions or natural body openings. For instance, in November 2023, Medtronic Plc, a US-based medical device manufacturer, received approval from the U.S. Food and Drug Administration (FDA) for Symplicity Spyral renal denervation (RDN). It is a minimally invasive device for treating hypertension. This innovative procedure employs radiofrequency energy to target nerves near the kidneys, effectively calming them to manage hypertension.

What Are Latest Mergers And Acquisitions In The Portal Hypertension Management Market?

In February 2023, AstraZeneca Plc, a UK-based pharmaceutical manufacturer, acquired CinCor Pharma Inc. for $1.8 billion. This acquisition broadens, diversifies, and enriches AstraZeneca's cardiorenal and hypertension pipeline by adding barostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension. CinCor Pharma Inc. is a US-based biotechnology company that develops and manufactures medication to lower blood pressure in treatment-resistant hypertension.

Regional Outlook

North America was the largest region in the portal hypertension management market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Portal Hypertension Management Market?

The portal hypertension management market consists of revenues earned by entities by provide services such as medical management, endoscopic therapy, interventional radiology procedures, and monitoring and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The portal hypertension management market also includes sales of nonselective beta-blockers, and vasoconstrictors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Portal Hypertension Management Market Report 2026?

The portal hypertension management market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the portal hypertension management industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.